Lex Orbis reports about a recent order passed by the Madras High Court, that too ex-parte, Hyderabad based Matrix Laboratories was restrained from making or selling generic version of Roche’s cancer drug erlotinib hydrochloride popularly know as Tarceva. The order comes in such a crucial time when the question of validity of the said drug is being adjudicated upon before the Delhi High Court in the high profile case of Roche vs Cipla. The issue there was the launch of generic version by Cipla, which costs around 4 times lesser than that of Roche’s patented drug. By way of this order, generic drugmaker Matrix is being temporarily injuncted for 2 months from launching the drug. It is unsure [...]

OUVRIR MON COMPTE CREATE MY ACCOUNT

  Un problème avec cet article ? / A problem with this article?